Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer
Lung Cancer · 2023-04 · 178 · 134-142
DOI: 10.1016/j.lungcan.2023.02.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lung Cancer, 2023-04. Verfasst von Liang Zeng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medi…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
INTRODUCTION: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Despite this, evidence supporting optimal management of certain stages remains a topic of debate. In this retrospective study we examine the efficacy and safety, as well as exploring the biomarkers of neoadjuvant induction immuno-chemotherapy, in Chinese patients with unresectable stage III NSCLC. METHODS: Patients with unresectable stage III NSCLC who were identified as driver mutation-negative and who received neoadjuvant chemo-immunotherapy were enrolled from three Chinese hospitals between Jan. 17, 2019, and Jan.17, 2022. Perioperative outcomes and survival data were collected. Retrospective biomarker exploration was performed in available baseline tumor samples and surgical specimens. RESULTS: 94 patients were enrolled and received chemo-immunotherapy as neoadjuvant treatment. 80 patients had squamous cell carcinoma, and 26 had stage IIIB disease. Surgery conversion rate was 74.4%, R0 resection rate was 98.4%. Of 64 patients who underwent surgery, major pathological response (MPR) rate was 65.6% and pathologic complete response (pCR) rate was 42.2%. 73% of patients with N2 disease demonstrated down-staging to N0. Treatment-related adverse events (TRAEs) occurred in 43 patients (45.7%) with anemia was the most common. The Grade ≥ 3 TRAEs rate was 3.2% (3/94). A significant association between copy number variation (CNV) ploidy was also found. CONCLUSION: The combination treatment of immuno-chemotherapy for unresectable stage III NSCLC is not only effective but also has a favourable safety profile. For the first time we provide evidence that CNV status may be a predictive biomarker of MPR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
- Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China; Graduate Colla…
- Department of Medical Oncology, Qinghai Provincial People's Hospital, Xining 810000, China.
- Department of Thoracic Surgery, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan 410008, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Zeng, L., Zhou, Y., Zhang, X., Xu, Q., Zhou, C., Zeng, F., Jiang, W., Wang, Z., Deng, L., Yang, H., Liu, L., Xiong, Y., Zhang, B., Yang, N., & Zhang, Y. (2023). Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer. Lung Cancer, 178, 134-142. https://doi.org/10.1016/j.lungcan.2023.02.017
Vancouver
Zeng L, Zhou Y, Zhang X, Xu Q, Zhou C, Zeng F, et al. Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer. Lung Cancer. 2023;178:134-142. doi:10.1016/j.lungcan.2023.02.017
BibTeX
@article{Zeng2023,
author = {Zeng, Liang and Zhou, Yuling and Zhang, Xiangyu and Xu, Qinqin and Zhou, Chunhua and Zeng, Fanxu and Jiang, Wenjuan and Wang, Zhan and Deng, Li and Yang, Haiyan and Liu, Li and Xiong, Yi and Zhang, Baihua and Yang, Nong and Zhang, Yongchang},
title = {Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer},
journal = {Lung Cancer},
year = {2023},
volume = {178},
pages = {134--142},
doi = {10.1016/j.lungcan.2023.02.017}
}
EUVIMED